Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Troponin | 4 | 2021 | 502 | 1.530 |
Why?
|
Anticholesteremic Agents | 5 | 2023 | 966 | 1.520 |
Why?
|
Atherosclerosis | 7 | 2024 | 3408 | 1.330 |
Why?
|
Cholesterol, LDL | 11 | 2024 | 2382 | 1.330 |
Why?
|
Lipoprotein(a) | 3 | 2024 | 480 | 1.300 |
Why?
|
Cardiovascular Diseases | 14 | 2024 | 15500 | 1.210 |
Why?
|
Chest Pain | 5 | 2019 | 1091 | 1.150 |
Why?
|
Cholesterol | 4 | 2024 | 2904 | 1.010 |
Why?
|
Glycopeptides | 3 | 2016 | 220 | 1.000 |
Why?
|
Oligonucleotides, Antisense | 3 | 2024 | 461 | 0.970 |
Why?
|
Cholesterol, VLDL | 1 | 2024 | 70 | 0.930 |
Why?
|
Triglycerides | 5 | 2024 | 2461 | 0.930 |
Why?
|
Endarterectomy | 2 | 2014 | 196 | 0.900 |
Why?
|
Myocardial Infarction | 9 | 2024 | 11460 | 0.870 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3245 | 0.860 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1866 | 0.850 |
Why?
|
Guilt | 1 | 2022 | 96 | 0.760 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 241 | 0.680 |
Why?
|
Apolipoproteins B | 5 | 2024 | 386 | 0.680 |
Why?
|
Ascorbic Acid Deficiency | 1 | 2019 | 25 | 0.670 |
Why?
|
Judgment | 1 | 2022 | 273 | 0.670 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 175 | 0.630 |
Why?
|
Pericarditis | 1 | 2019 | 135 | 0.590 |
Why?
|
Ticlopidine | 1 | 2022 | 730 | 0.570 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6403 | 0.540 |
Why?
|
Vascular Surgical Procedures | 3 | 2013 | 1489 | 0.500 |
Why?
|
Troponin I | 3 | 2016 | 651 | 0.500 |
Why?
|
Cardiovascular System | 1 | 2021 | 834 | 0.450 |
Why?
|
Alkalosis | 1 | 2013 | 55 | 0.450 |
Why?
|
Hypertension, Pulmonary | 2 | 2014 | 1578 | 0.440 |
Why?
|
Antacids | 1 | 2013 | 94 | 0.430 |
Why?
|
Pulmonary Embolism | 3 | 2020 | 2567 | 0.430 |
Why?
|
Atrial Fibrillation | 2 | 2023 | 5127 | 0.430 |
Why?
|
Self Medication | 1 | 2013 | 117 | 0.420 |
Why?
|
Risk Assessment | 11 | 2024 | 23995 | 0.420 |
Why?
|
Cardiology | 1 | 2024 | 1656 | 0.410 |
Why?
|
Dyslipidemias | 1 | 2020 | 868 | 0.410 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2021 | 1310 | 0.390 |
Why?
|
Cardiomyopathies | 1 | 2024 | 1964 | 0.390 |
Why?
|
Risk Factors | 16 | 2024 | 74206 | 0.390 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2001 | 0.380 |
Why?
|
Preoperative Period | 1 | 2013 | 551 | 0.380 |
Why?
|
Calcium | 1 | 2024 | 5722 | 0.360 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1303 | 0.350 |
Why?
|
Heart-Assist Devices | 1 | 2021 | 1287 | 0.350 |
Why?
|
Guideline Adherence | 1 | 2020 | 2220 | 0.350 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1390 | 0.340 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2022 | 2751 | 0.340 |
Why?
|
Lipoproteins | 3 | 2024 | 881 | 0.340 |
Why?
|
Foreign Bodies | 1 | 2013 | 402 | 0.330 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2014 | 628 | 0.320 |
Why?
|
Heart Atria | 1 | 2014 | 1345 | 0.300 |
Why?
|
Liver | 1 | 2023 | 7529 | 0.300 |
Why?
|
Humans | 46 | 2024 | 761504 | 0.280 |
Why?
|
Aged | 18 | 2024 | 169289 | 0.250 |
Why?
|
Middle Aged | 21 | 2024 | 220895 | 0.240 |
Why?
|
Angiopoietins | 1 | 2024 | 85 | 0.230 |
Why?
|
Female | 23 | 2024 | 392644 | 0.210 |
Why?
|
Genome-Wide Association Study | 3 | 2022 | 12690 | 0.210 |
Why?
|
Myocardial Ischemia | 1 | 2013 | 2113 | 0.210 |
Why?
|
Male | 22 | 2024 | 360804 | 0.210 |
Why?
|
Apolipoprotein C-III | 1 | 2024 | 211 | 0.200 |
Why?
|
Heart Ventricles | 1 | 2014 | 3807 | 0.200 |
Why?
|
Treatment Outcome | 10 | 2024 | 64680 | 0.200 |
Why?
|
Echocardiography | 1 | 2014 | 4989 | 0.190 |
Why?
|
Double-Blind Method | 4 | 2024 | 12341 | 0.190 |
Why?
|
Hypertriglyceridemia | 1 | 2024 | 293 | 0.180 |
Why?
|
Oligonucleotides | 1 | 2024 | 582 | 0.180 |
Why?
|
Subtilisins | 1 | 2020 | 81 | 0.180 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4028 | 0.180 |
Why?
|
Endophenotypes | 1 | 2022 | 255 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10209 | 0.180 |
Why?
|
Algorithms | 1 | 2020 | 14031 | 0.170 |
Why?
|
Scurvy | 1 | 2019 | 35 | 0.160 |
Why?
|
Heart Failure | 2 | 2021 | 11669 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 771 | 0.160 |
Why?
|
Niacin | 1 | 2019 | 118 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2022 | 467 | 0.150 |
Why?
|
Troponin T | 1 | 2022 | 780 | 0.150 |
Why?
|
Time Factors | 5 | 2024 | 39967 | 0.140 |
Why?
|
Down-Regulation | 1 | 2024 | 2919 | 0.140 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14605 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12463 | 0.140 |
Why?
|
Predictive Value of Tests | 6 | 2016 | 15266 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39106 | 0.130 |
Why?
|
Acute Coronary Syndrome | 2 | 2022 | 2190 | 0.130 |
Why?
|
Placebo Effect | 1 | 2019 | 518 | 0.130 |
Why?
|
Primary Prevention | 1 | 2023 | 1186 | 0.120 |
Why?
|
Adrenomedullin | 1 | 2015 | 85 | 0.120 |
Why?
|
Hypercholesterolemia | 1 | 2022 | 1141 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1051 | 0.120 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2023 | 1723 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1112 | 0.110 |
Why?
|
Mineralocorticoids | 1 | 2013 | 37 | 0.110 |
Why?
|
Laxatives | 1 | 2013 | 92 | 0.110 |
Why?
|
Bicarbonates | 1 | 2013 | 292 | 0.100 |
Why?
|
Hypokalemia | 1 | 2013 | 153 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2024 | 3826 | 0.100 |
Why?
|
Adult | 9 | 2024 | 221177 | 0.100 |
Why?
|
Language | 1 | 2021 | 1540 | 0.100 |
Why?
|
Gastritis | 1 | 2013 | 199 | 0.100 |
Why?
|
Prospective Studies | 4 | 2022 | 54425 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17904 | 0.090 |
Why?
|
Cohort Studies | 3 | 2024 | 41487 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58976 | 0.090 |
Why?
|
Protein Precursors | 1 | 2015 | 1132 | 0.090 |
Why?
|
Genetic Testing | 1 | 2024 | 3537 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2508 | 0.090 |
Why?
|
Diuretics | 1 | 2013 | 610 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2023 | 5112 | 0.090 |
Why?
|
Vomiting | 1 | 2013 | 651 | 0.090 |
Why?
|
Prognosis | 3 | 2023 | 29625 | 0.080 |
Why?
|
Fluid Therapy | 1 | 2013 | 579 | 0.080 |
Why?
|
Organ Size | 1 | 2014 | 2254 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2021 | 3312 | 0.080 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2013 | 575 | 0.080 |
Why?
|
ROC Curve | 1 | 2015 | 3579 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9610 | 0.070 |
Why?
|
Eating | 1 | 2013 | 1539 | 0.070 |
Why?
|
Postoperative Period | 1 | 2011 | 1813 | 0.070 |
Why?
|
Phenotype | 1 | 2024 | 16591 | 0.060 |
Why?
|
Genotype | 1 | 2019 | 12990 | 0.060 |
Why?
|
Registries | 1 | 2021 | 8224 | 0.060 |
Why?
|
Stroke | 2 | 2023 | 9757 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8002 | 0.060 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 2118 | 0.050 |
Why?
|
Electrocardiography | 2 | 2016 | 6377 | 0.050 |
Why?
|
Young Adult | 2 | 2023 | 59243 | 0.050 |
Why?
|
Incidence | 1 | 2020 | 21353 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5972 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10090 | 0.050 |
Why?
|
Sex Factors | 1 | 2014 | 10552 | 0.040 |
Why?
|
Africa | 1 | 2022 | 709 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15936 | 0.040 |
Why?
|
Hypolipidemic Agents | 1 | 2024 | 609 | 0.040 |
Why?
|
Heart Diseases | 1 | 2012 | 2781 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9318 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14666 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12947 | 0.040 |
Why?
|
Virulence | 1 | 2022 | 1303 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12974 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2024 | 1475 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20098 | 0.030 |
Why?
|
Patient Discharge | 2 | 2021 | 3443 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3422 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1787 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2022 | 1814 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3123 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2022 | 1387 | 0.030 |
Why?
|
Pravastatin | 1 | 2015 | 392 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2016 | 1186 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1702 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2016 | 80636 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2022 | 2811 | 0.020 |
Why?
|
Patient Admission | 1 | 2016 | 1367 | 0.020 |
Why?
|
Brain Ischemia | 1 | 2022 | 3049 | 0.020 |
Why?
|
Exercise Test | 1 | 2016 | 2127 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8631 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3416 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2016 | 7879 | 0.020 |
Why?
|
Acute Disease | 1 | 2015 | 7237 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5492 | 0.010 |
Why?
|
Up-Regulation | 1 | 2012 | 4124 | 0.010 |
Why?
|
Patient Readmission | 1 | 2016 | 3270 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6484 | 0.010 |
Why?
|
Odds Ratio | 1 | 2012 | 9646 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12148 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15842 | 0.010 |
Why?
|
Dextrans | 1 | 1954 | 574 | 0.010 |
Why?
|
Blood | 1 | 1954 | 596 | 0.010 |
Why?
|
Concepts
(170)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(51)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_